Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation;
Issues related to Medicare Part B, CMS coverage and reimbursement;
S. 2973, The Modernizing and Ensuring PBM Accountability (MEPA) Act;
H.R. 5378, The Lower Costs, More Transparency Act;
Issues related to Medicaid Drug Rebate Program
Issues related to Pandemic and All Hazards Preparedness Act (PAHPA) reauthorization;
Issues related to 340b drug pricing program;
Expiring healthcare extenders;
S. 1339, The Pharmacy Benefit Manager Reform Act;
H.R. 4366, the Consolidated Appropriations Act, 2024 (P.L. 118-42);
H.R. 2882, the Further Consolidated Appropriations Act, 2024 (P.L. 118-47);
Issues related to 340b
Issues related to biosecurity
Duration: January 1, 2021
to
present
General Issues: Medicare/Medicaid , Health Issues , Homeland Security , Taxation/Internal Revenue Code , Budget/Appropriations
Spending: about $680,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2021: U.S. Senate, House of Representatives, Executive Office of the President (EOP), Health & Human Services - Dept of (HHS)
Related Foreign Entities:
Roche Holdings AG (Basel Basel-stadt 4070, SUI); contribution to lobbying: $0; ownership 100%
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Tracy Spicer Deputy Chief of Staff, Political Director, Legislative Assistant,
Special Assistant, Staff Assistant - Sen. Edward Kennedy
Elizabeth Barnett Legislative Assistant, Speechwriter, Legislative Correspondent -
Sen. Blanche Lincoln; Staff Assistant - Senate Energy and Natural
Resources Committee
Amy Tejral Legislative Director, Sen. Ben Nelson
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, Avenue Solutions lobbied for Genentech USA, Inc. , earning $50,000. The report was filed on April 22.
Original Filing: 301574263.xml
Lobbying Issues
Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation;
Issues related to Medicare Part B, CMS coverage and reimbursement;
S. 2973, The Modernizing and Ensuring PBM Accountability (MEPA) Act;
H.R. 5378, The Lower Costs, More Transparency Act;
Issues related to Medicaid Drug Rebate Program
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Pandemic and All Hazards Preparedness Act (PAHPA) reauthorization;
Issues related to 340b drug pricing program;
Expiring healthcare extenders;
S. 1339, The Pharmacy Benefit Manager Reform Act;
H.R. 4366, the Consolidated Appropriations Act, 2024 (P.L. 118-42);
H.R. 2882, the Further Consolidated Appropriations Act, 2024 (P.L. 118-47);
Issues related to 340b
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to biosecurity
4th Quarter, 2023
In Q4, Avenue Solutions lobbied for Genentech USA, Inc. , earning $50,000. The report was filed on Jan. 22.
Original Filing: 301539369.xml
Lobbying Issues
Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation;
Issues related to Medicare Part B, CMS coverage and reimbursement;
Issues related to insulin out of pocket costs;
S. 954, Affordable Insulin Now Act of 2023;
S. 1269, INSULIN Act of 2023;
Issues related to healthcare access, quality and costs;
Issues related to orphan drugs;
Senate Finance Committees Better Mental Health Care, Lower Cost Drugs and Extenders Act (Discussion Draft);
S. 2973, The Modernizing and Ensuring PBM Accountability (MEPA) Act;
H.R. 5378, The Lower Costs, More Transparency Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Pandemic and All Hazards Preparedness Act (PAHPA) reauthorization;
Issues related to 340b drug pricing program;
Expiring healthcare extenders;
S. 1339, The Pharmacy Benefit Manager Reform Act
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2023
In Q3, Avenue Solutions lobbied for Genentech USA, Inc. , earning $50,000. The report was filed on Oct. 20, 2023.
Original Filing: 301510990.xml
Lobbying Issues
Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation;
Issues related to Medicare Part B, CMS coverage and reimbursement, 340b drug pricing program;
Issues related to insulin out of pocket costs;
S. 954, Affordable Insulin Now Act of 2023;
S. 1269, INSULIN Act of 2023;
Issues related to healthcare access, quality and costs;
Issues related to COVID rescissions
Lobbying Issues
Issues related to Pandemic and All Hazards Preparedness Act (PAHPA) reauthorization
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2023
In Q2, Avenue Solutions lobbied for Genentech USA, Inc. , earning $50,000. The report was filed on July 19, 2023.
Original Filing: 301483965.xml
Lobbying Issues
Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation;
Issues related to Medicare Part B, CMS coverage and reimbursement, 340b drug pricing program;
Issues related to insulin out of pocket costs;
S. 954, Affordable Insulin Now Act of 2023;
S. 1269, INSULIN Act of 2023;
Issues related to healthcare access, quality and costs;
Issues related to COVID rescissions
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to Pandemic and All Hazards Preparedness Act (PAHPA) reauthorization
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2023
In Q1, Avenue Solutions lobbied for Genentech USA, Inc. , earning $50,000. The report was filed on April 20, 2023.
Original Filing: 301464214.xml
Lobbying Issues
Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation;
Medicare Part B, CMS coverage and reimbursement, 340b drug pricing program
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2022
In Q4, Avenue Solutions lobbied for Genentech USA, Inc. , earning $50,000. The report was filed on Jan. 20, 2023.
Original Filing: 301440004.xml
Lobbying Issues
Issues related to Medicare Part B, CMS coverage and reimbursement, 340b drug pricing program;
S. 773, A bill to enable certain hospitals that were participating in or applied for the drug discount program under section 340B of the Public Health Service Act prior to the COVID-19 public health emergency to temporarily maintain eligibility for such program, and for other purposes;
S. 3799, PREVENT Pandemics Act;
S. 3700/H.R. 6833, Affordable Insulin Now Act;
Issues related to reauthorization of FDA user fee bills (H.R.7667, Food and Drug Amendments of 2022; S.4348 Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDSLA Act of 2022)), including accelerated approval and reimportation;
Issues related to the Public Health Emergency;
Issues related to the White House Cancer Moonshot initiative;
Issues related to accelerated approval;
Issues related to patient assistance programs and copay accumulators;
Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act;
Executive Order Directing HHS to Explore Additional Actions to Lower Prescription Drug Costs
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Inflation Reduction Act of 2022 (PL 117-169) - creating Medicare negotiation of drugs, creating a new inflation rebate under Medicare, limiting insulin copays to $35/month, capping Medicare Part D premium growth, expanding premium and co-pay assistance on prescription drugs for low-income individuals, and capping Medicare out of pocket costs at $2,000 per year, and preventing commercial spillover of maximum fair price into markets beyond Medicare;
Issues related to Continuing Resolution, H.R. 6833;
Issues related to Medicare Part B, CMS coverage and reimbursement, 340b drug pricing program;
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2022
In Q3, Avenue Solutions lobbied for Genentech USA, Inc. , earning $50,000. The report was filed on Oct. 20, 2022.
Original Filing: 301413206.xml
Lobbying Issues
Issues related to H.R. 5376, Inflation Reduction Act of 2022 (now PL 117-169) and implementation;
Issues related to the Continuing Resolution, H.R. 6833;
Issues related to Medicare Part B, CMS coverage and reimbursement, 340b drug pricing program;
Continued monitoring of Prescription Drug Pricing Reduction Act of 2019 from 116th Congress;
Continued monitoring of Elijah E. Cummings Lower Drug Costs Now Act from 116th Congress;
S. 773, A bill to enable certain hospitals that were participating in or applied for the drug discount program under section 340B of the Public Health Service Act prior to the COVID-19 public health emergency to temporarily maintain eligibility for such program, and for other purposes;
Issues related to the confluence of flu and COVID;
S. 3799, PREVENT Pandemics Act;
S. 3700/H.R. 6833, Affordable Insulin Now Act;
Issues related to reauthorization of FDA user fee bills (H.R.7667, Food and Drug Amendments of 2022; S.4348 Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDSLA Act of 2022)), including accelerated approval and reimportation;
Issues related to the Public Health Emergency;
H.R. 5585, The Advanced Research Project Agency-Health (ARPA-H) Act;
Issues related to the White House Cancer Moonshot initiative;
Issues related to accelerated approval;
Issues related to patient assistance programs and copay accumulators;
Issues related to the FY 2023 Presidents Budget;
Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2022
In Q2, Avenue Solutions lobbied for Genentech USA, Inc. , earning $50,000. The report was filed on July 20, 2022.
Original Filing: 301392027.xml
Lobbying Issues
Issues related to Medicare Part B, CMS coverage and reimbursement, 340b drug pricing program;
Continued monitoring of Prescription Drug Pricing Reduction Act of 2019 from 116th Congress;
Continued monitoring of Elijah E. Cummings Lower Drug Costs Now Act from 116th Congress;
Monitor possible healthcare policies in upcoming reconciliation package including: making ACA tax credits/subsidies permanent, addressing Medicaid coverage gap, expanding home and community based services, prescription drug reform;
H.R. 5376, Build Back Better Act;
S.773, A bill to enable certain hospitals that were participating in or applied for the drug discount program under section 340B of the Public Health Service Act prior to the COVID-19 public health emergency to temporarily maintain eligibility for such program, and for other purposes;
Issues related to the confluence of flu and COVID;
S.3799, PREVENT Pandemics Act;
S. 3700/H.R. 6833, Affordable Insulin Now Act;
Issues related to the Senate Finance report on mental health and mental health legislation;
Senate Finance Committee bipartisan Discussion Draft: Ensuring Access to Telemental Health Services;
Senate Finance Committee bipartisan Discussion Draft: Improving Access to Physical and Mental Health Care for Children and Youth under Medicaid and CHIP;
Bipartisan Safer Communities Act, P.L. 117-159, specifically policy related to access to mental health services for youth and families through Medicaid and CHIP and telehealth;
H.R. 7666, Restoring Hope for Mental Health and Well-Being Act of 2022;
Issues related to reauthorization of FDA user fee bills (H.R.7667, Food and Drug Amendments of 2022; S.4348 Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDSLA Act of 2022)), including accelerated approval and reimportation;
Issues related to the Public Health Emergency;
H.R. 5585, The Advanced Research Project Agency-Health (ARPA-H) Act;
Issues related to the White House Cancer Moonshot initiative;
Issues related to accelerated approval;
Issues related to patient assistance programs and copay accumulators;
Issues related to the FY 2023 Presidents Budget;
Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2022
In Q1, Avenue Solutions lobbied for Genentech USA, Inc. , earning $50,000. The report was filed on April 20, 2022.
Original Filing: 301370955.xml
Lobbying Issues
Issues related to Medicare Part B, CMS coverage and reimbursement, 340b drug pricing program;
Continued monitoring of Prescription Drug Pricing Reduction Act of 2019 from 116th Congress;
Continued monitoring of Elijah E. Cummings Lower Drug Costs Now Act from 116th Congress;
Monitor possible healthcare policies in upcoming reconciliation package including: making ACA tax credits/subsidies permanent, addressing Medicaid coverage gap, expanding home and community based services, prescription drug reform;
H.R. 5376, Build Back Better Act;
Issues surrounding federal government contracts to acquire doses of Xofluza;
S. 773, A bill to enable certain hospitals that were participating in or applied for the drug discount program under section 340B of the Public Health Service Act prior to the COVID-19 public health emergency to temporarily maintain eligibility for such program, and for other purposes;
Issues related to the confluence of flu and COVID;
Consolidated Appropriations Act, 2022 (PL 117-103);
S. 3799, PREVENT Pandemics Act;
S. 3700/H.R. 6833, Affordable Insulin Now Act;
Issues related to the Senate Finance report on mental health and mental health legislation;
Issues related to reauthorization of the FDA user fee bills;
Issues related to the Public Health Emergency
H.R. 5585, The Advanced Research Project Agency-Health (ARPA-H) Act;
Issues related to the White House Cancer Moonshot initiative;
Issues related to accelerated approval;
Issues related to patient assistance programs and copay accumulators;
H.R. 7007, COVID Supplemental Appropriations Act, 2022;
Issues related to the FY 2023 Presidents Budget
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to Medicare Part B, CMS coverage and reimbursement, 340b drug pricing program;
S. 3799, PREVENT Pandemics Act
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2021
In Q4, Avenue Solutions lobbied for Genentech USA, Inc. , earning $80,000. The report was filed on Jan. 19, 2022.
Original Filing: 301329841.xml
Lobbying Issues
Issues related to Medicare Part B, CMS coverage and reimbursement, 340b drug pricing program;
Continued monitoring of Prescription Drug Pricing Reduction Act of 2019 from 116th Congress;
Continued monitoring of Elijah E. Cummings Lower Drug Costs Now Act from 116th Congress;
Senate Finance Committee Drug Pricing Reform Principles;
Monitor possible healthcare policies in upcoming reconciliation package including: making ACA tax credits/subsidies permanent, adding Medicare enhancements/supplemental benefits (hearing, dental, vision), addressing Medicaid coverage gap, expanding home and community based services, prescription drug reform;
H.R. 5376, Build Back Better Act;
issues surrounding federal government contracts to acquire doses of Xofluza;
PL 117-58 - Infrastructure Investment and Jobs Act (BIF) - issues related to rebate rule delay, repurposed Provider Relief Funds, Medicare savings from single source vial size drug policy and extension of mandatory sequester)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to Medicare Part B, CMS coverage and reimbursement, 340b drug pricing program;
Continued monitoring of drug pricing legislation, including H.R. 3, Elijah E. Cummings Lower Drug Costs Now; Prescription Drug Pricing Reduction Act;
Senate Finance Committee Drug Pricing Reform Principles;
Proposed repeal of the CMS Rule on Most Favored Nation Model;
Delay of the Rebate Rule;
PL-117-71 Protecting Medicare and American Families from Sequester Cuts Act - specifically: 6 months relief from 2% Medicare sequester, 4% statutory Pay-As-You-Go Act, 1 year relief of physician conversion factor cuts, 1 year delay of clinical lab (PAMA) cuts, delay of radiation oncology demo
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2021
In Q3, Avenue Solutions lobbied for Genentech USA, Inc. , earning $50,000. The report was filed on Oct. 20, 2021.
Original Filing: 301313531.xml
Lobbying Issues
Issues related to Medicare Part B, CMS coverage and reimbursement, 340b drug pricing program;
Continued monitoring of Prescription Drug Pricing Reduction Act of 2019 from 116th Congress;
Continued monitoring of Elijah E. Cummings Lower Drug Costs Now Act from 116th Congress;
Senate Finance Committee Drug Pricing Reform Principles;
Monitor possible healthcare policies in upcoming reconciliation package including: making ACA tax credits/subsidies permanent, adding Medicare enhancements/supplemental benefits (hearing, dental, vision), addressing Medicaid coverage gap, expanding home and community based services, prescription drug reform;
H.R. 5376, Build Back Better Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to Medicare Part B, CMS coverage and reimbursement, 340b drug pricing program;
Continued monitoring of Prescription Drug Pricing Reduction Act of 2019 from 116th Congress;
Continued monitoring of Elijah E. Cummings Lower Drug Costs Now Act from 116th Congress;
Senate Finance Committee Drug Pricing Reform Principles;
Proposed repeal of the CMS Rule on Most Favored Nation Model;
Delay of the Rebate Rule
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2021
In Q2, Avenue Solutions lobbied for Genentech USA, Inc. , earning $50,000. The report was filed on July 20, 2021.
Original Filing: 301289624.xml
Lobbying Issues
Issues related to Medicare Part B, CMS coverage and reimbursement, 340b drug pricing program;
Continued monitoring of Prescription Drug Pricing Reduction Act of 2019 from 116th Congress;
Continued monitoring of Elijah E. Cummings Lower Drug Costs Now Act from 116th Congress;
Senate Finance Committee Drug Pricing Reform Principles;
Possible healthcare policies in upcoming reconciliation package including: making ACA tax credits/subsidies permanent, adding Medicare enhancements/supplemental benefits (hearing, dental, vision), addressing Medicaid coverage gap, expanding home and community based services;
Senate HELP and Energy & Commerce Public Option RFI
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to Medicare Part B, CMS coverage and reimbursement, 340b drug pricing program;
Continued monitoring of Prescription Drug Pricing Reduction Act of 2019 from 116th Congress;
Continued monitoring of Elijah E. Cummings Lower Drug Costs Now Act from 116th Congress;
Senate Finance Committee Drug Pricing Reform Principles
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to tax policy
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2021
In Q1, Avenue Solutions lobbied for Genentech USA, Inc. , earning $50,000. The report was filed on April 20, 2021.
Original Filing: 301262664.xml
Lobbying Issues
Issues related to Medicare Part B, CMS coverage and reimbursement, 340b drug pricing program;
Continued monitoring of Prescription Drug Pricing Reduction Act of 2019 from 116th Congress;
Continued monitoring of Elijah E. Cummings Lower Drug Costs Now Act from 116th Congress
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues/Medicaid
1st Quarter, 2021
Avenue Solutions filed a lobbying registration on Jan. 21, 2021 to represent Genentech USA, Inc., effective Jan. 1, 2021.
Original Filing: 301243304.xml
Issue(s) they said they’d lobby about: Issues related to Medicare Part B, CMS coverage and reimbursement, 340b, FDA and other appropriations matters .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...